Skip to content
NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP

Enovis Corp. ENOV

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.2B
▲ 6.7% YoY
$-1.2B
$19.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Enovis Corporation manufactures and distributes medical devices used for reconstructive surgery, rehabilitation, pain management and physical therapy. For the year ended December 31, 2025, approximately 42% of its net sales were derived from operations outside the United States, mostly in Europe with the remainder largely in the Asia-Pacific region. As of December 31, 2025, it employed approximately 7,802 persons, of whom approximately 2,107 were employed in the United States and approximately 5,695 outside of the United States. It reports its operations through the Prevention & Recovery and Reconstructive segments. Its Prevention & Recovery product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, and electrical stimulators used for pain management and physical therapy. Its Reconstructive segment provides implants, instrumentation and enabling technologies used in elective and non-elective joint replacement, limb reconstruction and foot and ankle procedures, serving orthopedic surgeons and healthcare systems worldwide with products for shoulder, hip, knee and extremity reconstruction and fixation. It was organized as a Delaware corporation in 1998.

Written from the business description in Enovis CORP's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.2B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.2 · Net income -1.2
2.0B4.0B-0.5B-1.0B
2009201220152018202120242025
Compound annual growth
+12.9%
+14.9%
−4.1%
+9.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−53 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -50.0% · Net -52.7%
5%-20%-40%
200920172025
ROE
FY2025 · ROE -58.5%
5%10%-20%-40%
200920172025
Three returns, three denominators.

Each USD of equity lost 58 cents this year.

Cash & shareholders

USD 2.2M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 19.9
150M300M-100M-200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 2.2
100.0M200.0M-250.0M-500.0M
20102012201420162018202020232025

USD 2.2M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 3.8B
EquityUSD 1.5B
CashUSD 36.4M
Gross debtUSD 1.3B
Net debtUSD 1.3B
Current ratio2.02×

Net debt stands at 85% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ENOV, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B2.22.11.71.61.41.13.32.21.93.23.44.64.23.90.70.50.5
Operating income $B−1.1−0.8−0.1−0.1−0.1−0.10.20.20.10.20.30.40.40.10.00.00.0
EBITDA $B0.20.20.20.10.10.10.40.20.20.40.40.60.50.30.00.1◌
Income tax $B0.00.0−0.00.0−0.0−0.00.0−0.00.00.10.0−0.10.10.10.00.00.0
Net income $B−1.2−0.8−0.0−0.00.10.0−0.50.10.20.10.20.40.2−0.10.00.00.0
Free cash flow $B0.0−0.10.0−0.20.30.20.00.20.20.20.20.30.30.10.00.00.0
EPS, diluted $−20.75−14.93−0.61−0.251.400.93−3.891.161.221.041.343.021.54−0.920.100.370.55
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %—————————————−001—
ROE %−58.5−27.6−1.0−0.31.81.2−15.74.14.74.35.413.98.1−6.12.27.511.0
Shares out B0.060.060.050.050.160.120.120.120.120.120.120.120.100.090.040.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 82 reconciliationsAUDITED

Reconciled in 16 of the 17 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image